Organic compounds

US8178559B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Werner Breitenstein · Basel, CH
• Takeru Ehara · Tsukuba, JP
• Claus Ehrhardt · Lörrach, DE
• Philipp Grosche · Inzlingen, DE
• Yuko Hitomi · Ibaraki, JP
• Yuki Iwaki · Cambridge, US
• Takanori Kanazawa · Tsukuba, JP
• Kazuhide Konishi · Ibaraki, JP
• Juergen Klaus Maibaum · Basel, CH
• Keiichi Masuya · Bottmingen, CH
• Atsuko Iwasaki · Ibaraki, JP
• Nils Ostermann · Binzen, DE
• Masaki Suzuki · Osaka, JP
• Atsushi Toyao · Tsukuba, JP
• Fumiaki Yokokawa · Singapore, SG

Key dates

• Filing date: Jul 6, 2011
• Grant date: May 15, 2012
• Expiry date: Jul 6, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

3,4-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,4-substituted piperidine compound, and/or a method of treatment comprising administering a 3,4substituted piperidine compound, a method for the manufacture of a 3,4-substituted piperidine compound, and novel intermediates and partial steps for their synthesis are disclosed. The 3,4-disubstituted piperidine compounds have the formula (I), wherein the symbols have the meanings defined in the specification.